| Characteristic | No. (%) of patients* | p value | |
|---|---|---|---|
| Achieved SVR n = 326 | Did not achieve SVR n = 25 | ||
| Age at treatment, median (IQR), yr | 57 (50-61) | 60 (56-64) | 0.02 |
| Sex | |||
| Male (n = 216) | 195 (90.3) | 21 (9.7) | 0.02 |
| Female (n = 135) | 131 (97.0) | 4 (3.0) | |
| Had previous treatment (n = 99) | 91 (91.9) | 8 (8.1) | 0.6 |
| Genotype (n = 350)† | |||
| 1a (n = 206) | 193 (93.7) | 13 (6.3) | 0.5 |
| 1b (n = 59) | 57 (96.6) | 2 (3.4) | 0.3 |
| 2 (n = 25) | 22 (88.0) | 3 (12.0) | 0.4 |
| 3 (n = 51) | 44 (86.3) | 7 (13.7) | 0.1 |
| 4 and 6 (n = 9) | 9 (100.0) | 0 (0.0) | 1.0 |
| FibroScan measurement at baseline, median (IQR), kPa | 10.2 (6.7-20.4) | 12.5 (7.6-26.3) | 0.1 |
| HCV RNA level at baseline, median (IQR), IU/mL | 701 684 (158 376-1 677 684) | 500 000 (94 082-1 500 000) | 0.5 |
| Chronic kidney disease at baseline (n = 16) | 16 (100.0) | 0 (0.0) | 0.6 |
| Estimated glomerular filtration rate at baseline, median (IQR), mL/min | 94 (81-101) | 96 (83-99) | 0.6 |
| Coinfection with HIV (n = 12) | 12 (100.0) | 0 (0.0) | 1.0 |
| Coinfection with HBV (n = 1) | 1 (100.0) | 0 (0.0) | 1.0 |
| Cirrhosis at baseline (n = 350) | |||
| Yes (n = 149) | 133 (89.3) | 16 (10.7) | 0.03 |
| No (n = 201) | 192 (95.5) | 9 (4.5) | |
| Previous history of hepatocellular carcinoma (n = 20) | 16 (80.0) | 4 (20.0) | 0.04 |
| Liver transplantation (n = 9) | 9 (100.0) | 0 (0.0) | 1.0 |
| Site | |||
| 1 (n = 11) | 11 (100.0) | 0 (0.0) | |
| 2 (n = 40) | 37 (92.5) | 3 (7.5) | 0.7 |
| 3 (n = 110) | 100 (90.9) | 10 (9.1) | |
| 4 (n = 190) | 178 (93.7) | 12 (6.3) | |
| Died during follow-up (n = 6) | 3 (50.0) | 3 (50.0) | < 0.01 |
| Development of hepatocellular carcinoma during follow-up (n = 12) | 11 (91.7) | 1 (8.3) | 0.6 |
| MELD score, median (IQR) | 6 (6-6) | 6 (6-6) | 1.0 |
| MELD with sodium score, median (IQR) | 7 (5-8) | 6 (5-8) | 0.9 |
Note: HBV = hepatitis B virus, HCV = hepatitis C virus, IQR = interquartile range, MELD = model for end-stage liver disease, SVR = sustained viral response.
*Except where noted otherwise.
†One patient was treated without an identified genotype and achieved an SVR.